Detalhe da pesquisa
1.
An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma.
Blood
; 141(10): 1159-1168, 2023 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36150143
2.
R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203.
Br J Haematol
; 204(3): 849-860, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37996986
3.
Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203.
Hematol Oncol
; 42(3): e3272, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38595316
4.
A phase II Japanese trial of 90-minute rituximab infusion for untreated B-cell lymphoma.
Jpn J Clin Oncol
; 54(4): 444-451, 2024 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38271157
5.
Long-term follow-up after R-High CHOP/CHASER/LEED with Auto-PBSCT in untreated mantle cell lymphoma-Final analysis of JCOG0406.
Cancer Sci
; 114(8): 3461-3465, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37232264
6.
Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.
Haematologica
; 108(3): 811-821, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36200417
7.
Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma: Phase IIb results.
Cancer Sci
; 113(8): 2778-2787, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35579212
8.
Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia-lymphoma.
Ann Hematol
; 101(4): 799-810, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35032188
9.
Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin's lymphoma: phase I safety and efficacy.
Jpn J Clin Oncol
; 52(9): 1014-1020, 2022 Sep 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35649345
10.
Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma.
Int J Clin Oncol
; 27(1): 213-223, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34599413
11.
CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
Cancer Sci
; 112(6): 2314-2324, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33792119
12.
Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.
Cancer Sci
; 112(3): 1123-1131, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33492746
13.
Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma.
Cancer Sci
; 112(6): 2426-2435, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33792128
14.
HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: An exploratory biomarker study of JCOG1105 (JCOG1105A1).
Cancer Sci
; 112(12): 5011-5019, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34626515
15.
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
N Engl J Med
; 379(10): 934-947, 2018 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30184451
16.
Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
Blood
; 133(2): 137-146, 2019 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30341058
17.
The role of local radiotherapy following rituximab-containing chemotherapy in patients with transformed indolent B-cell lymphoma.
Eur J Haematol
; 106(2): 213-220, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33098704
18.
Comparative effectiveness study of chemotherapy in follicular lymphoma patients in the rituximab era: a Japanese claims database study.
Future Oncol
; 17(4): 455-469, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33021099
19.
A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia.
Jpn J Clin Oncol
; 51(3): 408-415, 2021 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33244584
20.
Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea.
Jpn J Clin Oncol
; 51(2): 218-227, 2021 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33051668